Evaxion A/S · NASDAQ:EVAX
Evaxion A/S — Evaxion Biotech — Investor Presentation (November 2023)
38 slides from Evaxion A/S's investor presentation, November 2023
Slide 1: Evaxion AI-immunology Powered Vaccines
November 2023 evaxion-biotech.com EVAX:NASDAQ EVAXION AI-immunologyTM Powered Vaccines
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “
Slide 3: Executive Summary
Executive Summary Evaxion is a pioneering TechBio company with a validated and leading AI–platform (AI-immunologyTM) for fast and effective vaccine target discovery, design and development AI-immunologyTM allows for groundbreaking development of novel personalized and precision vaccines for cancer a
Slide 4: Our Strategy: Three-Pronged Business Model Based on AI-immunology Platform
Our Strategy: Three-Pronged Business Model Based on Our Leading AI-immunology™ Platform, Pursued via a Multi- Partner Approach The AI-immunology™ Platform Targets Multi partner approach focused around single • Design and development of personalized or multiple target discovery and validation and pre
Slide 5: Multidisciplinary Capabilities Create a Clearly Differentiated Position
The Multidisciplinary Capabilities Around AI-immunology™ and a Validated Platform Creates a Cleary Differentiated Position Registration Disease Risk of failure/cost Value of platform Clinical Target Phase 3 identification Clinical Target validation Evaxion Phase 2 AI-immunologyTM Clinical Platform A
Slide 6: Strong Leadership with Extensive Experience Across All Relevant Fields
Strong Leadership with Extensive Experience Across All Relevant Fields Board of Directors • Marianne Søgaard Chair, former tech lawyer and equity partner • Roberto Prego Former Teva (head of Latin America) • Lars Holtug Certified Public Accountant Chief Executive Chief Financial & Chief AI & Culture
Slide 7: Addressing a USD $277 billion and growing market for cancer immunotherapy
We are addressing a USD $277 Increased deal-making billion and growing market for across the vaccine space cancer immunotherapy alone Cancer Cancer • Cancer immunotherapy market estimated to grow to USD $277 • Moderna-Merck partnership. Upfront USD 200M (2016) + option billion by 2030* to exercise U
Slide 8: Evaxion is a Pioneering TechBio Company Based on AI-immunology Platform
Evaxion is a Pioneering TechBio Company Based on the Leading AI-immunologyTM Platform Founded in 2008 as an AI-Immunology company. Has extensively collected and applied data as well as refined and validated our AI platform for 15 years Three-pronged business model: Targets, Pipeline and Responders.
Slide 9: The AI-immunology Platform
The AI-immunology™ Platform
Slide 10: AI-immunology - a Unique Differentiator With Interrelated AI Prediction Models
AI-immunology™ - a Unique Differentiator With Interrelated AI Prediction Models and Leading Multidisciplinary Capabilities PIONEER AI-Deep Personalized and precision Prediction of vaccines for cancer responders to ObsERV immunotherapy Completely new targets treatment for cancer vaccines RAVEN Novel
Slide 11: AI-immunology discovery
PIONEER™ model Potential for Faster, PIONEER™ identifies the optimal neoantigens in a patients’ tumors for designing personalized cancer vaccines with the aim of eliciting an Cheaper and Lower immune response that finds and kills cancer cells in the patient. Risk Development ObsERV™ model Identifies
Slide 12: Our AI-immunology Platform and the Interrelated AI Prediction Models
Our AI-immunology™ Platform and the Interrelated AI Prediction Models 12
Slide 13: Platform is Delivery Modality Agnostic
A Unique Differentiation: The AI-immunology™ Platform is Delivery Modality Agnostic Competitor landscape personalized neoantigen vaccines • We have demonstrated that a key to more effective vaccines is the performance power Company Format Phase of our AI platform and the quality of the Moderna/Merck
Slide 14: PIONEER and ObsERV Allow for Discovery and Delivery of Personalized Cancer Vaccines
PIONEER™ and ObsERV™ Allow for Discovery and Delivery of Personalized Cancer Vaccines • We have shown that in as little as 7 • PIONEER™ and ObsERV™ are GXP compliant, which may weeks we can identify, manufacture enable FDA approval as a part of the manufacturing and deliver a completely personalized
Slide 15: EDEN and RAVEN Allow for Rapid Discovery and Validation of Novel Vaccine Targets
EDEN™ and RAVEN™ Allow for Rapid Discovery and Validation of Completely Novel Vaccine Targets for Infectious Diseases AI identification of vaccine antigens in 24 hours Inhouse preclinical validation and development Data processed on a supercomputer with powerful Streamlined processes for preclinical
Slide 16: Decoding the Immune System Will Enable Scalability Into Other Disease Areas
Decoding the Cellular Processes of the Immune System Will Enable Unique Scalability Into Other Disease Areas EDEN™ PIONEER™ ObsERV™ RAVEN™ AL TERI C S BA EASE VI S DI DI RAL SE GY LO - AS CO NO ES ON MU IM AI- AUTO SES DISEA immunology™ IMMU PA RA NE SI TE S S E SI M IO IO SB OB ALLERGIES DY ICR M 1
Slide 17: The AI-immunology Powered Vaccine Pipeline
The AI-immunology™ Powered Vaccine Pipeline
Slide 18: Demonstrating the Performance and Scalability of Our AI-immunology Platform
Demonstrating the Performance and Scalability of Our AI- immunology™ Platform 18
Slide 19: EVX-01 shows Overall Response Rate of 67% in Phase 1/2
EVX-01 in combination with standard therapy shows Overall Response Rate of 67% in clinical Individual patient responses Phase 1/2 in patients with metastatic melanoma Study highlights • 12 patients in total, with 8 showing an objective response to treatment (ORR 67%) • 2 complete responders • Treatm
Slide 20: EVX-01 PIONEER Identified Vaccine Targets Highly Correlate With Survival
EVX-01 PIONEER Identified Vaccine Targets Highly Correlate With Survival Progression Free Survival based on PIONEER score High prediction score of neoantigens (N=6) • AI response prediction (PIONEER Low prediction score of neoantigens (N=6) score) builds on the presence of high-quality tumor neoanti
Slide 21: EVX-01 induces a dose-dependent immune response
EVX-01 induces a dose- Dose-dependent increase in neoantigen- dependent immune specific T cells (tumor killing cells) response against the patients’ cancer Neoantigen-specific T cells (SFU) • A higher dose induced higher neoantigen immune responses which may result in stronger tumor killing activity
Slide 22: EVX-01 Clinical Phase 1/2 Summary
EVX-01 – Clinical Phase 1/2 Summary: With AI-immunology™ identified targets we have demonstrated longer progression free survival of patients Phase 1/2 Phase 2 High overall response rate with clinical Phase 2 initiated in metastatic response in all high dose group patients melanoma with high dose EV
Slide 23: EVX-01 Phase 2 Trial Enrolling Patients in Australia/Europe
EVX-01 Phase 2 Trial Enrolling Patients in Australia/Europe Enrolled 16 patients with metastatic melanoma Conducted in collaboration with Merck & Co., Inc (MSD) EVX-01 Priming EVX-01 Boosting Production (To activate T-cells) (To maintain level of activated T-cells) Timeline for each W1 W12 W14 W16 W
Slide 24: EVX-02 first DNA-based personalized cancer vaccine shows positive readout
EVX-02 Evaxion’s first DNA-based Positive clinical personalized cancer vaccine shows readout* positive clinical readout Study overview: • All 10 EVX-02 completers were relapse-free at last assessment • Phase 1/2 clinical trial of EVX-02 + nivolumab (Opdivo™/standard of care) as adjuvant therapy afte
Slide 25: EVX-03 – Believed To Be First Ever Personalized ERV Vaccine
EVX-03 – Believed To Be First Ever Personalized ERV Vaccine DNA-based personalized vaccine armed with molecular immune adjuvant, neoantigens and ERVs • Molecular immune adjuvant attracts antigen presenting cells and augments antigen presentation • The unique technology is fully owned, patent protect
Slide 26: EVX-03 Addition of ERVs Resulted in Very Promising Preclinical Data
EVX-03 Addition of ERVs Resulted in Very Promising Preclinical Data • ERVs are ancient viruses that have ERV-based DNA vaccine prevents High ERV burden is associated with integrated into the genome and are tumor growth in preclinical model better survival in patients with few passed down through gen
Slide 27: EVX-B1 S. aureus Vaccine Candidate
EVX-B1 S. aureus Vaccine Candidate Demonstrating High Immunogenicity and Significant Protection • Multi-component S. aureus vaccine candidate for prevention Mouse sepsis model of Skin and Soft Tissue Infections (SSTI) 100 EVX-B1 Adjuvant • Induction of high IgG titers and 80 Buffer Survival (%) pote
Slide 28: EVX-B2 N. gonorrhoeae Vaccine Candidate
EVX-B2 N. gonorrhoeae Vaccine Candidate Induce Significant Protection and Shows Broad Neutralization Capacity • Multi-component N. gonorrhea Vaginal colonization model vaccine candidate containing two top-ranked EDEN candidates 106 Adjuvant EVX-B2 Bacterial burden (CFU) • Significant protection agai
Slide 29: Intellectual Property
Intellectual Property
Slide 30: Intellectual Property Portfolio Broadly Covers AI and Vaccine Candidates
Evaxion’s Intellectual Property Portfolio Broadly Covers AI and Vaccine Candidates for Cancer and Infectious Diseases Evaxion Biotech A/S holds an extensive intellectual property (IP) portfolio The IP portfolio covers AI-immunologyTM and everything related to our two disease areas: Cancer and infect
Slide 31: Corporate Summary
Corporate Summary
Slide 32: Several important near-term milestones across all three parts of our strategy
Several important near-term milestones across all three parts of our strategy to monetize on AI-immunology™ Ph2 interim data Ph2 1Y readout EVX-01 Targets Infectious disease Leading pharma, Afrigen and Expres2ion collaborations collaborations on track for value creation Pipeline Several discussion a
Slide 33: Capital Structure
Capital Structure Listed on Nasdaq NY under ticker “EVAX” Date of listing: Feb 5, 2021 Headquarters Denmark Employees 50 Average Volume (3M) 216,190 Shares outstanding 28 M Cash June 30 2023 (USD) 7.1 M Institutional investors 0.5 – 1% Capital raised (USD) 86 M Fully diluted share count 30 M Debt (U
Slide 34: Recent Deals Overview
Recent Deals Overview EVX-B3: Discovery partnership Afrigen - mRNA Gonorrhea vaccine Description Description • Discovery partnership with leading pharmaceutical • Discovery partnership to design and test mRNA Gonorrhea company around undisclosed bacterial pathogen for vaccine, based on EDEN™ identif
Slide 35: Summary
Summary The AI-immunology™ Platform Targets Multiple partnerships in place, several partner • Design and development of personalized discussion ongoing. Dealmaking capacity and precision vaccine candidates being enhanced • AI prediction models trained in oncology Pipeline and infectious diseases EVX
Slide 36: Thank You
For more information Visit us at Or contact us at: evaxion-biotech.com evaxion-biotech.com CEO Christian Kanstrup NON-CONFIDENTIAL [email protected] Thank You AI-immunologyTM Powered Vaccines
Slide 37: Appendices
November 2023 evaxion-biotech.com Appendices
Slide 38: Our Promise When Going Public / Our Achievement
OUR PROMISE WHEN OUR GOING PUBLIC ACHIEVEMENT To become a world Leader in, With AI-immunology™ identified AI-Immunology decoding the targets we have demonstrated human immune system for Our improved Progression Free effective AI-powered vaccines Survival of patients in a clinical development setting
Evaxion Biotech — Investor Presentation (November 2023) on 6ix